Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 23, 2018updated 02 Nov 2021 7:08am

B. Braun to buy bloodlines business from NxStage Medical

Medical products developer B. Braun Medical has entered into an agreement to purchase a bloodlines business from medical technology company NxStage Medical.

Medical products developer B. Braun Medical has entered into an agreement to purchase a bloodlines business from medical technology company NxStage Medical.

Operated under the Medisystems brand, the bloodlines business contains a portfolio of blood tubing solutions intended for the elimination of blood-air interfaces. The blood tubing products are called Streamline Long, Streamline Express and Streamline.

The business’s portfolio also contains a tubing product called Reverso, which allows easy blood flow reversal during treatment.

“The deal is subject to Federal Trade Commission approval and contingent upon the closing of the pending merger between NxStage Medical and a unit of Fresenius Medical.”

Braun expects the acquisition, which will expand the company’s dialysis product range, to facilitate better promotion of Streamline.

Braun Medical vice-president Sam Amory said: “We are pleased to add the Streamline bloodline to our dialysis product portfolio.

“Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog haemodialysis machine and the Diacap PRO dialyser.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

The deal is subject to Federal Trade Commission approval and contingent upon the closing of the pending merger between NxStage Medical and a unit of Fresenius Medical.

Braun anticipates completing its acquisition of the bloodlines business this year.

The company develops, manufactures and markets new medical products and services for the healthcare market. It primarily focuses on renal therapies, infusion therapy and pain management.

It aims to eliminate preventable treatment errors and improve patient, clinician and environmental safety.

With more than 61,000 employees across 64 countries, B. Braun’s sister companies include B. Braun Interventional Systems, Aesculap and CAPS.

Related Companies

Topics in this article: , ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU